{"preliminary_commentary":{"by_channel":{"x_thread":2,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"NCT03765918","nct_id":"NCT03765918","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=nct03765918. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Neoadjuvant treatment: Participants received 200 mg pembrolizumab by intravenous (IV) infusion administered on Day 1 of a 21-day cycle for 2 cycles (up to 6 weeks) prior to surgery.\n\nAdjuvant treatment: Following surgical resection, participants received 200 mg pembrolizumab, IV infusion, on Day 1 of a 21-day cycle for 15 cycles (up to 45 weeks) plus investigator's choice of SOC treatment regimen consisting of radiotherapy, with or without cisplatin 100 mg/m\\^2, IV infusion, on Day 1 of a 21-day cycle for 3 cycles (up to 9 weeks).","label":"Pembrolizumab + Standard of Care (SOC)","type":"EXPERIMENTAL"},{"description":"Adjuvant treatment: Following surgical resection, participants received investigator's choice of SOC treatment regimen consisting of radiotherapy, with or without cisplatin 100 mg/m\\^2, IV infusion, on Day 1 of a 21-day cycle for 3 cycles (up to 9 weeks).","label":"Standard of Care (SOC)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2026-11-17","type":"ESTIMATED"},"conditions":["Head and Neck Neoplasms"],"enrollment":{"count":714,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Pembrolizumab 200 mg","otherNames":["KEYTRUDA®","MK-3475"],"type":"BIOLOGICAL"},{"name":"Radiotherapy 60 Gray","otherNames":[],"type":"RADIATION"},{"name":"Radiotherapy 66 Gray","otherNames":[],"type":"RADIATION"},{"name":"Radiotherapy 70 Gray","otherNames":[],"type":"RADIATION"},{"name":"Cisplatin 100 mg/m^2","otherNames":["Platinol®","Platinol-AQ®"],"type":"DRUG"}],"last_update":"2026-07-31","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"A Phase III, Randomized, Open-label Study to Evaluate Pembrolizumab as Neoadjuvant Therapy and in Combination With Standard of Care as Adjuvant Therapy for Stage III-IVA Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA HNSCC)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2024-07-25","type":"ACTUAL"},"primary_outcomes":[{"measure":"Event-free Survival (EFS)","timeFrame":"Up to ~66 months"},{"measure":"EFS in Participants With Programmed Cell Death Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10","timeFrame":"Up to ~66 months"},{"measure":"EFS in Participants With PD-L1 CPS ≥1","timeFrame":"Up to ~66 months"}],"references":[{"citation":"Uppaluri R, Haddad RI, Tao Y, Le Tourneau C, Lee NY, Westra W, Chernock R, Tahara M, Harrington KJ, Klochikhin AL, Brana I, Vasconcelos Alves G, Hughes BGM, Oliva M, Pinto Figueiredo Lima I, Ueda T, Rutkowski T, Schroeder U, Mauz PS, Fuereder T, Laban S, Oridate N, Popovtzer A, Mach N, Korobko Y, Costa DA, Hooda-Nehra A, Rodriguez CP, Bell RB, Manschot C, Benjamin K, Gumuscu B, Adkins D; KEYNOTE-689 Investigators. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer. N Engl J Med. 2025 Jul 3;393(1):37-50. doi: 10.1056/NEJMoa2415434. Epub 2025 Jun 18.","pmid":"40532178","type":"DERIVED"}],"start_date":{"date":"2018-12-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)","url":"https://clinicaltrials.gov/study/NCT03765918"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/nct03765918"}